Erica Weitz1, Steven D Hollon2, Ad Kerkhof3, Pim Cuijpers4. 1. Department of Clinical Psychology, VU University Amsterdam, The Netherlands; EMGO Institute for Health and Care Research, VU University and VU University Medical Center Amsterdam, The Netherlands. Electronic address: e.weitz@vu.nl. 2. Vanderbilt University, Nashville, TN, USA. 3. Department of Clinical Psychology, VU University Amsterdam, The Netherlands; EMGO Institute for Health and Care Research, VU University and VU University Medical Center Amsterdam, The Netherlands. 4. Department of Clinical Psychology, VU University Amsterdam, The Netherlands; EMGO Institute for Health and Care Research, VU University and VU University Medical Center Amsterdam, The Netherlands; Leuphana University, Lüneburg, Germany.
Abstract
BACKGROUND: Many well-researched treatments for depression exist. However, there is not yet enough evidence on whether these therapies, designed for the treatment of depression, are also effective for reducing suicidal ideation. This research provides valuable information for researchers, clinicians, and suicide prevention policy makers. METHODS: Analysis was conducted on the Treatment for Depression Research Collaborative (TDCRP) sample, which included CBT, IPT, medication, and placebo treatment groups. Participants were included in the analysis if they reported suicidal ideation on the HRSD or BDI (score of ≥1). RESULTS: Multivariate linear regression indicated that both IPT (b=.41, p<.05) and medication (b =.47, p<.05) yielded a significant reduction in suicide symptoms compared to placebo on the HRSD. Multivariate linear regression indicated that after adjustment for change in depression these treatment effects were no longer significant. Moderate Cohen׳s d effect sizes from baseline to post-test differences in suicide score by treatment group are reported. LIMITATIONS: These analyses were completed on a single suicide item from each of the measures. Moreover, the TDCRP excluded participants with moderate to severe suicidal ideation. CONCLUSIONS: This study demonstrates the specific effectiveness of IPT and medications in reducing suicidal ideation (relative to placebo), albeit largely as a consequence of their more general effects on depression. This adds to the growing body of evidence that depression treatments, specifically IPT and medication, can also reduce suicidal ideation and serves to further our understanding of the complex relationship between depression and suicide.
RCT Entities:
BACKGROUND: Many well-researched treatments for depression exist. However, there is not yet enough evidence on whether these therapies, designed for the treatment of depression, are also effective for reducing suicidal ideation. This research provides valuable information for researchers, clinicians, and suicide prevention policy makers. METHODS: Analysis was conducted on the Treatment for Depression Research Collaborative (TDCRP) sample, which included CBT, IPT, medication, and placebo treatment groups. Participants were included in the analysis if they reported suicidal ideation on the HRSD or BDI (score of ≥1). RESULTS: Multivariate linear regression indicated that both IPT (b=.41, p<.05) and medication (b =.47, p<.05) yielded a significant reduction in suicide symptoms compared to placebo on the HRSD. Multivariate linear regression indicated that after adjustment for change in depression these treatment effects were no longer significant. Moderate Cohen׳s d effect sizes from baseline to post-test differences in suicide score by treatment group are reported. LIMITATIONS: These analyses were completed on a single suicide item from each of the measures. Moreover, the TDCRP excluded participants with moderate to severe suicidal ideation. CONCLUSIONS: This study demonstrates the specific effectiveness of IPT and medications in reducing suicidal ideation (relative to placebo), albeit largely as a consequence of their more general effects on depression. This adds to the growing body of evidence that depression treatments, specifically IPT and medication, can also reduce suicidal ideation and serves to further our understanding of the complex relationship between depression and suicide.
Authors: Jennifer L Vande Voort; Elizabeth D Ballard; David A Luckenbaugh; Rebecca A Bernert; Erica M Richards; Mark J Niciu; Lawrence T Park; Rodrigo Machado-Vieira; Wallace C Duncan; Carlos A Zarate Journal: J Clin Psychiatry Date: 2017 Sep/Oct Impact factor: 4.384
Authors: Angela M Bengtson; Brian W Pence; Katie R Mollan; Jessie K Edwards; Richard D Moore; Conall OʼCleirigh; Ellen F Eaton; Joseph J Eron; Mari M Kitahata; William C Mathews; Heidi Crane; Michael J Mugavero Journal: J Acquir Immune Defic Syndr Date: 2017-12-01 Impact factor: 3.731
Authors: Elizabeth D Ballard; David A Luckenbaugh; Erica M Richards; Tessa L Walls; Nancy E Brutsché; Rezvan Ameli; Mark J Niciu; Jennifer L Vande Voort; Carlos A Zarate Journal: J Psychiatr Res Date: 2015-06-16 Impact factor: 4.791
Authors: Gabriela K Khazanov; Colin Xu; Steven D Hollon; Robert J DeRubeis; Michael E Thase Journal: J Affect Disord Date: 2020-12-08 Impact factor: 4.839
Authors: Wendy Marie Ingram; Anna M Baker; Christopher R Bauer; Jason P Brown; Fernando S Goes; Sharon Larson; Peter P Zandi Journal: Neurol Psychiatry Brain Res Date: 2020-02-21